Acorda Therapeutics, Inc.
NASDAQ:ACOR
0.661 (USD) • At close April 11, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 117.633 | 118.566 | 129.071 | 152.967 | 192.408 | 471.433 | 588.287 | 519.601 | 492.66 | 401.48 | 336.43 | 305.814 | 292.237 | 191.005 | 54.673 | 47.827 | 39.486 | 27.351 | 5.146 | 0.479 | 0.856 |
| Cost of Revenue
| 46.047 | 30.332 | 40.787 | 33.513 | 34.849 | 99.31 | 135.714 | 108.109 | 92.931 | 80.615 | 66.643 | 57.641 | 66.567 | 35.518 | 11.389 | 11.355 | 8.356 | 7.123 | 5.132 | 5.302 | 0 |
| Gross Profit
| 71.586 | 88.234 | 88.284 | 119.454 | 157.559 | 372.123 | 452.573 | 411.492 | 399.729 | 320.865 | 269.787 | 248.173 | 225.67 | 155.487 | 43.284 | 36.472 | 31.13 | 20.228 | 0.013 | -4.823 | 0.856 |
| Gross Profit Ratio
| 0.609 | 0.744 | 0.684 | 0.781 | 0.819 | 0.789 | 0.769 | 0.792 | 0.811 | 0.799 | 0.802 | 0.812 | 0.772 | 0.814 | 0.792 | 0.763 | 0.788 | 0.74 | 0.003 | -10.058 | 1 |
| Reseach & Development Expenses
| 5.152 | 5.804 | 10.42 | 23.012 | 60.083 | 106.383 | 166.105 | 203.437 | 149.209 | 73.47 | 53.877 | 53.881 | 42.108 | 30.6 | 34.611 | 36.604 | 22.41 | 12.055 | 12.89 | 21.999 | 34.27 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 172.254 | 181.619 | 235.437 | 205.63 | 201.813 | 0 | 168.69 | 0 | 133.317 | 31.98 | 73.307 | 48.167 | 31.64 | 21.533 | 17.945 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | -0.32 | -17.552 | 0 | 0 | 0 | 0 | 0 | 0 | 57.951 | 49,069.841 | 30,736.544 | 19,079.013 | 13,098.595 | 0 | 0 |
| SG&A
| 89.698 | 106.256 | 124.399 | 152.576 | 192.845 | 172.254 | 181.299 | 217.885 | 205.63 | 201.813 | 185.545 | 168.69 | 148.508 | 133.317 | 89.931 | 73.307 | 48.167 | 31.64 | 21.533 | 17.945 | 0 |
| Other Expenses
| 0.051 | 18.21 | 30.764 | 30.763 | 25.636 | -18.063 | -19.071 | -6.287 | -14.621 | -8.382 | -1.502 | -1.334 | 64.183 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 29.065 |
| Operating Expenses
| 94.85 | 130.27 | 165.583 | 206.351 | 278.564 | 278.637 | 347.404 | 421.322 | 354.839 | 275.283 | 239.422 | 222.571 | 190.616 | 163.917 | 124.542 | 109.911 | 70.577 | 43.695 | 34.423 | 39.944 | 63.335 |
| Operating Income
| -23.264 | -42.036 | -77.299 | -86.897 | 14.548 | 38.486 | -232.814 | -35.981 | 33.99 | 36.391 | 30.365 | 25.602 | 35.054 | -8.43 | -81.258 | -73.439 | -39.447 | -23.467 | -34.41 | -44.767 | -62.479 |
| Operating Income Ratio
| -0.198 | -0.355 | -0.599 | -0.568 | 0.076 | 0.082 | -0.396 | -0.069 | 0.069 | 0.091 | 0.09 | 0.084 | 0.12 | -0.044 | -1.486 | -1.536 | -0.999 | -0.858 | -6.687 | -93.363 | -72.989 |
| Total Other Income Expenses Net
| -272.757 | 6.789 | -31.775 | -20.77 | -288.795 | -73.063 | -357.054 | -32.438 | -25.521 | -17.573 | -1.502 | -1.334 | -3.036 | -3.339 | -2.683 | 0.008 | 0.051 | 0.075 | 0.001 | 0.002 | -0.636 |
| Income Before Tax
| -296.021 | -35.247 | -109.074 | -107.667 | -274.247 | 20.423 | -251.885 | -42.268 | 19.369 | 28.009 | 28.863 | 24.268 | 32.018 | -11.77 | -83.94 | -73.431 | -39.397 | -23.391 | -34.408 | -44.764 | -63.115 |
| Income Before Tax Ratio
| -2.516 | -0.297 | -0.845 | -0.704 | -1.425 | 0.043 | -0.428 | -0.081 | 0.039 | 0.07 | 0.086 | 0.079 | 0.11 | -0.062 | -1.535 | -1.535 | -0.998 | -0.855 | -6.687 | -93.358 | -73.732 |
| Income Tax Expense
| -43.167 | 30.669 | -5.12 | -8.073 | -1.282 | -13.259 | -28.526 | -6.665 | 8.311 | 10.337 | 12.422 | -130.69 | 1.413 | -0.591 | -1.732 | 0.893 | -0.869 | 0.477 | 1.12 | -0.029 | -0.033 |
| Net Income
| -252.854 | -65.916 | -103.954 | -99.594 | -272.965 | 33.682 | -223.359 | -34.618 | 11.058 | 17.672 | 16.441 | 154.958 | 30.605 | -11.769 | -83.941 | -74.341 | -37.974 | -24.019 | -35.53 | -44.741 | -62.446 |
| Net Income Ratio
| -2.15 | -0.556 | -0.805 | -0.651 | -1.419 | 0.071 | -0.38 | -0.067 | 0.022 | 0.044 | 0.049 | 0.507 | 0.105 | -0.062 | -1.535 | -1.554 | -0.962 | -0.878 | -6.905 | -93.308 | -72.951 |
| EPS
| -203.59 | -66.9 | -195.75 | -246.4 | -689.42 | 85.98 | -582.69 | -91.79 | 31.42 | 51.53 | 49.07 | 471.25 | 93.6 | -36.82 | -266.94 | -262.85 | -173.68 | -157.11 | -20,851.08 | -27,181.51 | -38,834.58 |
| EPS Diluted
| -203.59 | -66.9 | -195.75 | -246.4 | -689.42 | 85.38 | -583.2 | -91.79 | 30 | 50.4 | 46.8 | 460.8 | 91.2 | -36.82 | -266.94 | -262.85 | -173.68 | -157.11 | -20,851.08 | -27,181.51 | -38,834.58 |
| EBITDA
| 8.402 | -10.03 | -44.796 | -64.955 | 40.184 | 148.486 | 443.152 | 16.321 | 55.79 | 54.773 | 30.365 | 25.602 | 38.09 | -5.091 | -78.575 | -73.001 | -39.498 | -21.96 | -32.599 | -41.7 | -61.843 |
| EBITDA Ratio
| 0.071 | -0.085 | -0.347 | -0.425 | 0.209 | 0.315 | 0.753 | 0.031 | 0.113 | 0.136 | 0.09 | 0.084 | 0.13 | -0.027 | -1.437 | -1.526 | -1 | -0.803 | -6.335 | -86.966 | -72.246 |